Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer

Next Previous
X
Search
Trial Profile

A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipatasertib (Primary) ; Paclitaxel
  • Indications Carcinoma; Early breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms FAIRLANE
  • Sponsors Genentech

    • Most Recent Events

    • 14 Dec 2021 Results assessing the characterize AKT signaling activity and its association with other genomic or immunohistochemistry-based PI3K/AKT pathway biomarkers as well as the clinical activity of ipatasertib, published in the Clinical Cancer Research.
    • 14 Dec 2019 Results assessing charecterization of PD-L1 expression by using sample data from this study presented at the 42nd Annual San Antonio Breast Cancer Symposium.
    • 30 May 2019 Safety and efficacy results published in the Annals of Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top